Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352964 | 0.94 | ADORA2A (0.50) | ADORA2AADORA2BSLC29A1ADORA3ADORA1 | |
| SCHEMBL5347819 | 0.90 | ADORA2A (0.60) | ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL5347799 | 0.90 | ADORA2A (0.60) | ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL5356824 | 0.90 | ADORA2A (0.60) | ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL5352841 | 0.89 | ADORA2A (0.52) | ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL5358560 | 0.86 | ADORA2A (0.53) | ADORA2AADORA2BSLC29A1ADORA3 | |
| SCHEMBL217116 | 0.81 | CYP2C19 (0.60) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL9347680 | 0.81 | ADORA2A (0.56) | ADORA2AADORA2BSLC29A1ADORA3ADORA1 | |
| SCHEMBL1611240 | 0.80 | ADORA2A (0.57) | ADORA2AADORA2BSLC29A1ADORA3ADORA1 | |
| SCHEMBL4813930 | 0.80 | ADORA2A (0.57) | ADORA2AADORA2BSLC29A1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307166-B1 | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | PRO-NEURON, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1157698-A2 | Treatment of inflammatory diseases with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6060459-A | Enhancing blood cell count with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| US-6054441-A | Antiinflammatory agents; treatment of bacterial, viral or fungal infections; autoimmune diseases | PRO-NEURON, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| EP-0570519-B1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO NEURON INC (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0771204-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0570519-A4 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO NEURON INC (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0570519-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013561-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | TPMT, NUDT1, ENTPD5 | ADORA2A 61/4885ADORA2B 113/4885SLC29A1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.